Elliott Vichinsky, MD: Voxelotor and New HOPE Data
Dec 08, 2020, 11:48 PM
The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.
The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.
We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.
You can visit our support center if you're having problems.